NCT00686686已完成3 期
A Multi Center, Open Label, Single-Arm Study to Evaluate the Efficacy of Infliximab Induction Therapy for Patients With Palmoplantar Psoriasis (PPP), Including the Pustular Form (PsPPP)
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 23
- 主要终点
- Number of Participants Who Achieve at Least 75% Improvement in Palmoplantar Psoriasis Activity Severity Index (PPPASI) After 3 Infusions.
研究概览
简要总结
Subjects with psoriasis will receive intravenous infliximab 5 mg/kg given over a 2-hour period at Weeks 0, 2, and 6 (induction therapy) to evaluate the efficacy of infliximab at Week 18. Subjects who achieved >=75% improvement in Psoriasis Pustulosa Palmoplantaris Area and Severity Index (PPPASI) score at Week 8 AND had deterioration of PPPASI score of 50% from Week 8 until Week 12 were to receive an additional infusion at Week 12.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18-70 years of age at time of enrollment; male or female.
- •Women of childbearing potential and all men must be using adequate birth control measures and should continue using such measures until 6 months after receiving the last infusion of study agent.
- •Plaque-type psoriasis with evidence of mild to moderate psoriasis elsewhere or Psoriasis Pustulosa Palmo Plantaris (PPPP) of 6 months duration at least.
- •Adhere to study visit schedule and other protocol requirements.
- •Capable of giving informed consent prior to any study related procedures.
- •Avoid prolonged sun exposure, including tanning booths or other ultraviolet (UV) light sources during the study.
- •Eligible according to country-specific tuberculosis (TB) screening, eligibility assessment, and prevention rules.
- •Chest x-ray within 3 months prior to first infusion with no evidence of malignancy, infection, or fibrosis.
- •Screening laboratory test results within parameters specified in protocol.
排除标准
- •Have any other form of psoriasis besides palmoplantaris and the pustular form.
- •Pregnant, nursing, or planning pregnancy within 6 months after last infusion.
- •Previous treatment with infliximab or any therapeutic agent targeted at reducing tumor-necrosis factor (TNF), including but not limited to etanercept, thalidomide, CDP870, or D2E
- •Other inflammatory disease that might confound the evaluations of benefit from the infliximab therapy, including but not limited to, rheumatoid arthritis (RA), ankylosing spondylitis, systemic lupus erythematosus, Lyme disease.
- •Used any investigational drug within the previous 1 month or 5 times the half life of the investigational agent, whichever is longer, or 3 months for any biologic of unknown half life.
- •Received any systemic medications/treatments that could affect psoriasis or PASI evaluation within 1 month prior to study.
- •Used topical medications/treatments that could affect psoriasis or PASI evaluation within 2 or 4 weeks of baseline visit.
- •Treated with any anti-CD4 antibody in the last 6 month.
- •Received any systemic immunosuppressive within 4 weeks prior to first infusion.
- •Received within 3 months prior to first infusion or are expected to receive any live virus or bacterial vaccinations during the trial or up to 3 months after the last infusion.
- •History of chronic or recurrent infectious disease, including but not limited to chronic renal infection, chronic chest infection, recurrent urinary tract infection, or open, draining or infected skin wounds or ulcers.
- •Serious infection or been hospitalized or received IV antibiotics for an infection during the previous 2 months.
- •Have or had opportunistic infection.
- •Herpes zoster infection within 2 months of baseline.
- •Infected with human immunodeficiency virus (HIV), hepatitis B or C.
- •History of any clinically significant adverse events (AEs) to murine or chimeric proteins or human/murine recombinant products.
- •Current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, cerebral, or psychiatric disease.
- •History of demyelinating disease or symptoms suggestive of multiple sclerosis or optic neuritis.
- •Systemic lupus erythematosus.
- •Transplanted organ.
- •History of lymphoproliferative disease, including lymphoma, or signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy of unusual size or location.
- •Malignancy within previous 5 years.
- •Concomitant diagnosis of congestive heart failure (CHF).
- •Unable or unwilling to undergo multiple venipunctures because of poor tolerability or lack of easy access to veins.
- •Substance abuse problem within previous 3 years.
- •Hypersensitivity reaction/adverse reaction to paracetamol/acetaminophen, antihistamines, topical corticosteroids.
- •Participation in another trial using an investigational agent or procedure during this trial.
结局指标
主要结局
Number of Participants Who Achieve at Least 75% Improvement in Palmoplantar Psoriasis Activity Severity Index (PPPASI) After 3 Infusions.
时间窗: Baseline and Week 8
The PPPASI score is an overall score of disease signs: extent, scales, erythema, erosions (fissures), induration and pustules. "Extent" is rated on a scale range from 0-6; all other signs are rated on a scale range from 0 to 4 in a target palm and/or sole. Total score range:0-26. A reduction in score is considered an improvement.
次要结局
- Number of Participants Who Achieve a Moderate Response.(Baseline and Week 8)
- Number of Participants Achieving Clear to Minimal PGA Score at Weeks 12 and 18.(Weeks 12 and 18)
- Number of Participants Who Respond to the Fourth Infusion.(Week 12 and Week 18)
- Dermatology Life Quality Index (DLQI)(Baseline and Week 12)
研究者
相似试验
已完成
3 期
A Study to Evaluate Infliximab in Subjects With Moderate-to-Severe Psoriasis Not Responding to Standard or Biologic Therapy (Study P04612)PsoriasisNCT00687401Merck Sharp & Dohme LLC215
已完成
4 期
A Study to Assess Efficacy and Tolerability of Topical Skincare Products on Psoriasis PatientsPsoriasisPlaque PsoriasisNCT06357221Galderma R&D46
已完成
3 期
Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque PsoriasisPsoriasisNCT01878461Maruho North America Inc.542
Unknown
1 期
A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118Plaque PsoriasisNCT01670513Dow Pharmaceutical Sciences60
未知
2 期
M518101 phase 2b study in plaque psoriasis patients - comparison study 2Plaque psoriasisJPRN-jRCT2080221434Maruho Co.,Ltd.